Open Access

Clinical value of lncRNA CCAT1 in serum extracellular vesicles as a potential biomarker for gastric cancer

  • Authors:
    • Ke Xiao
    • Zhaogang Dong
    • Ding Wang
    • Min Liu
    • Juan Ding
    • Wendan Chen
    • Ziqi Shang
    • Congbo Yue
    • Yi Zhang
  • View Affiliations

  • Published online on: April 6, 2021     https://doi.org/10.3892/ol.2021.12708
  • Article Number: 447
  • Copyright: © Xiao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Long non‑coding RNAs (lncRNAs) in extracellular vesicles (EVs) are considered to be novel non‑invasive biomarkers for gastric cancer (GC). lncRNA colon cancer‑associated transcript 1 (CCAT1) is aberrantly expressed in certain types of cancer. However, the role of EV lncRNA CCAT1 in patients with GC remains unclear. The current study aimed to assess the expression levels of lncRNA CCAT1 in the serum EVs of patients with GC and evaluate its potential clinical value. EVs were isolated from serum using a commercial kit and ultracentrifugation, and were identified by transmission electron microscopy, nanoparticle tracking analysis and western blotting. Serum EV lncRNA CCAT1 levels in patients with GC, chronic gastritis or atypical hyperplasia and healthy control subjects were detected by reverse transcription‑quantitative PCR. Additionally, lncRNA CCAT1 was detected in GC and adjacent non‑cancerous tissue samples. Serum EVs were successfully isolated and identified in all patients. The results revealed that serum EV lncRNA CCAT1 levels in patients with GC were significantly higher compared with those in healthy controls, patients with chronic gastritis or atypical hyperplasia (all P<0.05). Additionally, EV lncRNA CCAT1 expression levels were significantly different among various groups based on the depth of invasion, distant metastasis and the Tumor‑Node‑Metastasis stage. The area under the curve (AUC) value of EV lncRNA CCAT1 was 0.890 [95% confidence interval (CI), 0.826‑0.937] with 79.6% sensitivity and 92.6% specificity. The combination of EV lncRNA CCAT1 and carcinoembryonic antibody produced an AUC value of 0.910 (95% CI, 0.849‑0.951) with the sensitivity and specificity of 80.5 and 92.6%, respectively. In addition, lncRNA CCAT1 was determined to be stable in serum EVs. The expression levels of lncRNA CCAT1 in GC tissue were positively correlated with those in serum EVs, and high levels of lncRNA CCAT1 were associated with a low disease‑free survival rate in patients with GC. The results of the present study demonstrated that serum EV lncRNA CCAT1 levels were upregulated in patients with GC compared with those healthy subjects and patients with other illnesses, and may therefore be used as a novel biomarker for this type of cancer.
View Figures
View References

Related Articles

Journal Cover

June-2021
Volume 21 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xiao K, Dong Z, Wang D, Liu M, Ding J, Chen W, Shang Z, Yue C and Zhang Y: Clinical value of lncRNA CCAT1 in serum extracellular vesicles as a potential biomarker for gastric cancer. Oncol Lett 21: 447, 2021
APA
Xiao, K., Dong, Z., Wang, D., Liu, M., Ding, J., Chen, W. ... Zhang, Y. (2021). Clinical value of lncRNA CCAT1 in serum extracellular vesicles as a potential biomarker for gastric cancer. Oncology Letters, 21, 447. https://doi.org/10.3892/ol.2021.12708
MLA
Xiao, K., Dong, Z., Wang, D., Liu, M., Ding, J., Chen, W., Shang, Z., Yue, C., Zhang, Y."Clinical value of lncRNA CCAT1 in serum extracellular vesicles as a potential biomarker for gastric cancer". Oncology Letters 21.6 (2021): 447.
Chicago
Xiao, K., Dong, Z., Wang, D., Liu, M., Ding, J., Chen, W., Shang, Z., Yue, C., Zhang, Y."Clinical value of lncRNA CCAT1 in serum extracellular vesicles as a potential biomarker for gastric cancer". Oncology Letters 21, no. 6 (2021): 447. https://doi.org/10.3892/ol.2021.12708